Compare Revolution Medicines Inc. Common Stock (RVMD) vs Toast Inc. Class A Common Stock (TOST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revolution Medicines Inc. Common Stock vs Toast Inc. Class A Common Stock — how do they compare? Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B), while Toast Inc. Class A Common Stock trades at $29.53 (market cap $17.85B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 2.3× Toast Inc. Class A Common Stock's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Toast Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| RVMD | TOST | |
|---|---|---|
Market Cap | $40.39B | $17.85B |
Volume | 2,941,009 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $221.15 | $39.02 |
52-Week Low | $49.56 | $22.33 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $37.09B | $16.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →About Toast Inc. Class A Common Stock
Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →
